Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Cancer Cell

Volumn 2, Issue 2, 2002, Pages 117-125

  Shah, Neil P ^a   Nicoll, John M ^a   Nagar, Bhushan ^c   Gorre, Mercedes E ^a   Paquette, Ronald L ^a   Kuriyan, John ^b,c   Sawyers, Charles L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; GELDANAMYCIN; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

AMINO ACID ANALYSIS; ARTICLE; BLOOD EXAMINATION; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CODON; CORRELATION ANALYSIS; CRYSTAL STRUCTURE; GENE AMPLIFICATION; GENE IDENTIFICATION; GENE MUTATION; GENE SEGREGATION; GENOMICS; HUMAN; NONHUMAN; PRIORITY JOURNAL; ALLELE; AMINO ACID SEQUENCE; CELL CLONE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG RESISTANCE; GENETICS; METABOLISM; MUTATION; NOTE; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROTEIN TERTIARY STRUCTURE; RECURRENT DISEASE; TIME; TUMOR RECURRENCE;

ALLELES; AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; CLONE CELLS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MODELS, MOLECULAR; MUTATION; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; RECURRENCE; TIME FACTORS;

EID: 0001686739     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00096-X     Document Type: Article

References (34)

1. Allen, P.B., and Wiedemann, L.M. (1996). An activating mutation in the ATP binding site of the ABL kinase domain. J. Biol. Chem. 271, 19585-19591.
2. Barthe, C., Cony-Makhoul, P., Melo, J.V., and Mahon, J.R. (2001). Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163.
3. Branford, S., Rudzki, Z., Walsh, S., Grigg, A., Arthur, C., Taylor, K., Herrmann, R., Lynch, K.P., and Hughes, T.P. (2002). High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR-ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99, 3472-3475.
4. Daley, G.Q., and Baltimore, D. (1988). Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210BCR/ABL protein. Proc. Natl. Acad. Sci. USA 85, 9312-9316.
5. Daley, G.Q., Van Etten, R.A., and Baltimore, D. (1990). Induction of chronic myelogenous leukemia in mice by the P210 BCR-ABL gene of the Philadelphia chromosome. Science 247, 824-830.
6. Druker, B.J., Sawyers, C.L., Kantarjian, H., Resta, D.J., Reese, S.F., Ford, J.M., Capdeville, R., and Talpaz, M. (2001a). Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344, 1038-1042.
7. Druker, B.J., Talpaz, M., Resta, D.J., Peng, B., Buchdunger, E., Ford, J.M., Lydon, N.B., Kantarjian, H., Capdeville, R., Ohno-Jones, S., and Sawyers, C.L. (2001b). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
8. Elefanty, A.G., Hariharan, I.K., and Cory, S. (1990). BCR-ABL, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J. 9, 1069-1078.
9. Evans, S.V. 1993. SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. J. Mol. Graph. 11, 134-138, 127-128.
10. Gambacorti-Passerini, C., Barni, R., le Coutre, P., Zucchetti, M., Cabrita, G., Cleris, L., Rossi, F., Gianazza, E., Brueggen, J., Cozens, R., et al. (2000). Role of alphal acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the ABL inhibitor STI571. J. Natl. Cancer Inst. 92, 1641-1650.
11. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N., and Sawyers, C.L. (2001a). Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880.
12. Gorre, M.E., Shah, N.P., Ellwood, K.B., Nicoll, J.M., and Sawyers, C.L. (2001b). Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163a.
13. Gorre, M.E., Ellwood-Yen, K.B., Chiosis, G., Rosen, N., and Sawyers, C.L. (2002). BCR-ABL point mutants isolated from patients with STI571-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood, in press. Published online June 7, 2002. 10.1182/blood-2002 05-1367.
14. Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., Lahaye, T., Berger, U., Cross, N.C., Linkesch, W., Druker, B.J., Hehlmann, R., et al. (2001). Roots of clinical resistance to STI-571 cancer therapy. Science 293, 2163.
15. Hofmann, W.K., Jones, L.C., Lemp, N.A., de Vos, S., Gschaidmeier, H., Hoelzer, D., Ottmann, O.G., and Koeffler, H.P. (2002). Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99, 1860-1862.
16. Hubbard, S.R. (1997). Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572-5581.
17. Jackson, P.K., Paskind, M., and Baltimore, D. (1993). Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl. Oncogene 8, 1943-1956.
18. Jorgensen, H.G., Elliott, M.A., Allan, E.K., Carr, C.E., Holyoake, T.L., and Smith, K.D. (2002). Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571. Blood 99, 713-715.
19. Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002). Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 346, 645-652.
20. Kelliher, M.A., McLaughlin, J., Witte, O.N., and Rosenberg, N. (1990). Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR-ABL. Proc. Natl. Acad. Sci. USA 87, 6649-6653.
21. Kharbanda, S., Pandey, P., Jin, S., Inoue, S., Bharti, A., Yuan, Z.M., Weichselbaum, R., Weaver, D., and Kufe, D. (1997). Functional interaction between DNA-PK and c-Abl in response to DNA damage. Nature 386, 732-735.
22. Mahon, F.X., Deininger, M.W., Schultheis, B., Chabrol, J., Reiffers, J., Goldman, J.M., and Melo, J.V. (2000). Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 96, 1070-1079.
23. Nagar, B., Bornmann, W., Pellicena, P., Schindler, T., Veach, D., Miller, W.T., Clarkson, B., and Kuriyan, J. (2002). Crystal structures of the kinase domain of c-ABL in complex with the small molecule inhibitors PD173955 and STI571. Cancer Res., in press.
24. Roumiantsev, S., Shah, N.P., Gorre, M.E., Nicoll, J.M., Brasher, B.B., Sawyers, C.L., and Van Etten, R.A. (2002). Clinical resistance to the kinase inhibitor STI-571 in CML by mutation of Tyr253 in the ABL kinase domain P-loop. Proc. Natl. Acad. Sci. USA, in press.
25. Salloukh, H.F., and Laneuville, P. (2000). Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase. Leukemia 14, 1401-1404.
26. Sawyers, C.L. (1999). Chronic myeloid leukemia. N. Engl. J. Med. 340, 1330-1340.
27. Sawyers, C.L., Hochhaus, A., Feldman, E., Goldman, J.M., Miller, C.B., Ottmann, O.G., Schiffer, C.A., Talpaz, M., Guilhot, F., Deininger, M.W., et al. (2002). Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99, 3530-3539.
28. Schindler, T., Bornmann, W., Pellicena, P., Miller, W.T., Clarkson, B., and Kuriyan, J. (2000). Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942.
29. Shafman, T., Khanna, K.K., Kedar, P., Spring, K., Kozlov, S., Yen, T., Hobson, K., Gatei, M., Zhang, N., Watters, D., et al. (1997). Interaction between ATM protein and c-Abl in response to DNA damage. Nature 387, 520-523.
30. Talpaz, M., Silver, R.T., Druker, B.J., Goldman, J.M., Gambacorti-Passerini, C., Guilhot, F., Schiffer, C.A., Fischer, T., Deininger, M.W., Lennard, A.L., et al. (2002). Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 99, 1928-1937.
31. Vogelstein, B., and Kinzler, K.W. (1997). The Genetic Basis of Human Cancer (New York: McGraw-Hill).
32. von Bubnoff, N., Schneller, F., Peschel, C., and Duyster, J. (2002). BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet 359, 487-491.
33. Yamaguchi, H., and Hendrickson, W.A. (1996). Structural basis for activation of human lymphocyte kinase LCK upon tyrosine phosphorylation. Nature 384, 484-489.
34. Yoshida, K., Komatsu, K., Wang, H.G., and Kufe, D. (2002). c-ABL tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage. Mol. Cell. Biol. 22, 3292-3300.